James Patterson, PhD
Psychiatry · Shreveport, LANPI 1619995198
Payments from drug & device makers
Across 48 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$244
- Neurocrine Biosciences, Inc.$122
- Otsuka America Pharmaceutical, Inc.$117
- Teva Pharmaceuticals USA, Inc.$103
- Lundbeck LLC$94
- Johnson & Johnson$88
- plus $110 from 4 others
What the payments were for
- Food & beverage$879100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 13 | $244 |
| Neurocrine Biosciences, Inc. | 7 | $122 |
| Otsuka America Pharmaceutical, Inc. | 7 | $117 |
| Teva Pharmaceuticals USA, Inc. | 6 | $103 |
| Lundbeck LLC | 5 | $94 |
| Johnson & Johnson | 4 | $88 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Sunovion Pharmaceuticals Inc. | 2 | $34 |
| Indivior Inc. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
How this compares
$879 in reported general payments places this provider in the 55th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 29 | $4,562 |
| Gabapentin | 15 | $1,955 |
| Clozapine | 15 | $1,435 |
| Phenobarbital | 40 | $1,433 |
| Lorazepam | 200 | $1,400 |
| Valproic AcidValproic Acid (As Sodium Salt) | 12 | $920 |
| Levetiracetam | 18 | $620 |
| Clonazepam | 57 | $525 |
| Trazodone Hcl | 26 | $368 |
| Sertraline Hcl | 36 | $306 |
| Quetiapine Fumarate | 18 | $286 |
| Risperidone | 31 | $215 |
| Desmopressin Acetate | 12 | $214 |
| Prazosin Hcl | 12 | $126 |
| Olanzapine | 13 | $108 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Shreveport
- Guy BrannonShreveport$1.4M
- Gregory BrownShreveport$495K
- Jasjit SinghShreveport$420K
- James BookerShreveport$204K
- Shawn McNeilShreveport$105K
- Matthew MenardShreveport$101K
- Suresh SabbenahalliShreveport$10K
- Christopher BernadasShreveport$6K
- Daniel FeeneyShreveport$5K
- Kashinath YadalamLake Charles$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.